Ontology highlight
ABSTRACT:
SUBMITTER: Xu H
PROVIDER: S-EPMC9658092 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature
Xu Huizhe H Zhang Ye Y Liu Jia J Cui Jing J Gan Yu Y Wu Zhisheng Z Chang Youwei Y Sui Rui R Chen Yi Y Shi Ji J Liang Haiyang H Liu Qiang Q Sun Shulan S Piao Haozhe H
Cancers 20221029 21
UM-164 is a dual inhibitor of c-Src and p38 MAPK, and has been a lead compound for targeting triple-negative breast cancer. UM-164 shows stronger binding to the active sites of Src compared with the conventional Src inhibitor Dasatinib. While Dasatinib has displayed some inhibitory effects on glioma growth in clinical trials, whether UM-164 can suppress glioma growth has not been reported. Here we show that UM-164 suppressed the proliferation, migration and spheroid formation of glioma cells, an ...[more]